Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
Status:
Terminated
Trial end date:
2019-07-12
Target enrollment:
Participant gender:
Summary
This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate
the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in
pediatric subjects with TS.